ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for PRTA

Stock NameProthena Corporation plc
TickerPRTA(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINIE00B91XRN20

Show aggregate PRTA holdings

News associated with PRTA

Prothena Corporation plc (NASDAQ:PRTA) Receives $30.25 Average PT from Brokerages
Shares of Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) have received a consensus rating of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on […] - 2025-08-19 04:26:55
Chicago Partners Investment Group LLC Buys 3,315 Shares of Prothena Corporation plc (NASDAQ:PRTA)
Chicago Partners Investment Group LLC grew its holdings in Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 29.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,512 shares of the biotechnology company’s stock after buying an additional 3,315 shares during the period. Chicago […] - 2025-08-13 05:18:49
TD Asset Management Inc Reduces Stock Position in Prothena Corporation plc (NASDAQ:PRTA)
TD Asset Management Inc cut its stake in Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 3.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,694 shares of the biotechnology company’s stock after selling 2,000 shares during the period. TD Asset Management […] - 2025-08-05 04:37:17
Brokerages Set Prothena Corporation plc (NASDAQ:PRTA) Target Price at $31.50
Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) has earned an average recommendation of “Hold” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have issued a buy recommendation on the company. […] - 2025-07-25 05:12:48
Alps Advisors Inc. Has $470,000 Stake in Prothena Corporation plc (NASDAQ:PRTA)
Alps Advisors Inc. trimmed its position in shares of Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 12.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,956 shares of the biotechnology company’s stock after selling 5,554 shares during the period. Alps Advisors Inc. […] - 2025-07-15 06:59:50
Cambridge Investment Research Advisors Inc. Acquires New Stake in Prothena Corporation plc (NASDAQ:PRTA)
Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Prothena Corporation plc (NASDAQ:PRTA – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,164 shares of the biotechnology company’s stock, valued at approximately $126,000. A number of […] - 2025-07-15 04:17:25
SG Americas Securities LLC Raises Stock Holdings in Prothena Corporation plc (NASDAQ:PRTA)
SG Americas Securities LLC increased its position in Prothena Corporation plc (NASDAQ:PRTA – Free Report) by 92.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,559 shares of the biotechnology company’s stock after acquiring an additional 34,947 shares during the period. SG […] - 2025-06-19 04:30:54
Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Two Sigma Investments LP
Two Sigma Investments LP increased its stake in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 265.4% during the 4th quarter, Holdings Channel reports. The fund owned 38,394 shares of the biotechnology company’s stock after purchasing an additional 27,887 shares during the quarter. Two Sigma Investments LP’s holdings in Prothena were worth $532,000 as of […] - 2025-06-09 04:30:53
Hennion & Walsh Asset Management Inc. Buys 25,353 Shares of Prothena Co. plc (NASDAQ:PRTA)
Hennion & Walsh Asset Management Inc. lifted its holdings in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 48.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 77,637 shares of the biotechnology company’s stock after purchasing an additional 25,353 shares during the period. Hennion & Walsh Asset […] - 2025-06-08 05:53:06
Bank of America Corp DE Acquires 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA)
Bank of America Corp DE increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 45.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 119,007 shares of the biotechnology company’s stock after buying an additional 36,944 shares […] - 2025-06-05 05:14:52
Prothena (NASDAQ:PRTA) Earns “Underperform” Rating from Bank of America
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating restated by stock analysts at Bank of America in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. A number of other analysts have also recently weighed in on PRTA. Cantor Fitzgerald cut shares of Prothena from an “overweight” rating to […] - 2025-05-30 05:06:52
Bank of America Reaffirms Underperform Rating for Prothena (NASDAQ:PRTA)
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating restated by research analysts at Bank of America in a note issued to investors on Wednesday, MarketBeat.com reports. A number of other equities analysts have also issued reports on PRTA. Cantor Fitzgerald lowered shares of Prothena from an “overweight” rating to a “neutral” rating […] - 2025-05-30 05:06:52
Prothena (NASDAQ:PRTA) Receives “Underperform” Rating from Bank of America
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating reiterated by Bank of America in a research note issued to investors on Wednesday, Marketbeat Ratings reports. PRTA has been the topic of several other reports. Cantor Fitzgerald cut shares of Prothena from an “overweight” rating to a “neutral” rating in a report on […] - 2025-05-30 05:06:52
Prothena (NASDAQ:PRTA) Given Underperform Rating at Bank of America
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “underperform” rating reiterated by stock analysts at Bank of America in a note issued to investors on Wednesday, MarketBeat.com reports. PRTA has been the topic of a number of other reports. Wall Street Zen upgraded Prothena from a “sell” rating to a “hold” rating in a […] - 2025-05-30 05:06:52
Prothena (NASDAQ:PRTA) Downgraded by Jefferies Financial Group to “Hold”
Prothena (NASDAQ:PRTA – Get Free Report) was downgraded by stock analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a report issued on Tuesday, Marketbeat Ratings reports. They presently have a $6.00 price target on the biotechnology company’s stock. Jefferies Financial Group’s target price indicates a potential upside of 30.43% […] - 2025-05-29 03:02:58
JMP Securities Lowers Prothena (NASDAQ:PRTA) Price Target to $29.00
Prothena (NASDAQ:PRTA – Get Free Report) had its target price cut by JMP Securities from $78.00 to $29.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. A number of other equities analysts have also commented on the company. Wall Street Zen raised Prothena […] - 2025-05-29 03:02:57
Prothena (NASDAQ:PRTA) Rating Lowered to Neutral at Cantor Fitzgerald
Prothena (NASDAQ:PRTA – Get Free Report) was downgraded by research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, MarketBeat reports. Several other equities research analysts have also recently issued reports on PRTA. Royal Bank of Canada lowered their price objective […] - 2025-05-29 03:02:53
HC Wainwright Cuts Prothena (NASDAQ:PRTA) Price Target to $14.00
Prothena (NASDAQ:PRTA – Get Free Report) had its price objective decreased by analysts at HC Wainwright from $30.00 to $14.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 204.35% from the company’s current […] - 2025-05-29 02:15:04
Piper Sandler Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price
Prothena (NASDAQ:PRTA – Free Report) had its target price decreased by Piper Sandler from $110.00 to $81.00 in a research report released on Tuesday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the biotechnology company’s stock. A number of other research firms have also commented on PRTA. Oppenheimer lowered Prothena from an “outperform” […] - 2025-05-28 04:46:49
Chardan Capital Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price
Prothena (NASDAQ:PRTA – Free Report) had its price objective lowered by Chardan Capital from $40.00 to $18.00 in a research note released on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. A number of other equities research analysts have also recently commented on the stock. Oppenheimer raised their […] - 2025-05-28 02:52:54
Traders Purchase High Volume of Put Options on Prothena (NASDAQ:PRTA)
Prothena Co. plc (NASDAQ:PRTA – Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock traders bought 8,185 put options on the company. This is an increase of approximately 1,210% compared to the average volume of 625 put options. Prothena Price Performance Shares of PRTA stock opened at $4.58 on Wednesday. […] - 2025-05-28 02:06:46
Balyasny Asset Management L.P. Makes New $527,000 Investment in Prothena Co. plc (NASDAQ:PRTA)
Balyasny Asset Management L.P. acquired a new position in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 38,021 shares of the biotechnology company’s stock, valued at approximately $527,000. Balyasny Asset Management L.P. […] - 2025-05-16 05:52:58
Raymond James Financial Inc. Takes Position in Prothena Co. plc (NASDAQ:PRTA)
Raymond James Financial Inc. purchased a new stake in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 13,111 shares of the biotechnology company’s stock, valued at approximately $182,000. Several other institutional investors and […] - 2025-05-13 04:18:47
Prothena (NASDAQ:PRTA) Price Target Lowered to $30.00 at HC Wainwright
Prothena (NASDAQ:PRTA – Free Report) had its price objective reduced by HC Wainwright from $48.00 to $30.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other brokerages have also weighed in on PRTA. Piper Sandler boosted their price objective on shares […] - 2025-05-12 02:44:45
JMP Securities Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock Price
Prothena (NASDAQ:PRTA – Free Report) had its target price reduced by JMP Securities from $80.00 to $78.00 in a report published on Friday morning,Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock. A number of other equities research analysts also recently issued reports on the stock. Cantor Fitzgerald reiterated an […] - 2025-05-12 02:44:45
Hsbc Holdings PLC Grows Holdings in Prothena Co. plc (NASDAQ:PRTA)
Hsbc Holdings PLC increased its stake in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 60.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 24,179 shares of the biotechnology company’s stock after purchasing an additional 9,101 shares during the period. Hsbc Holdings PLC’s holdings […] - 2025-05-09 05:41:02
Renaissance Technologies LLC Acquires 19,100 Shares of Prothena Co. plc (NASDAQ:PRTA)
Renaissance Technologies LLC increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 10.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,900 shares of the biotechnology company’s stock after purchasing an additional 19,100 shares during the period. […] - 2025-04-25 05:54:49
Corebridge Financial Inc. Trims Position in Prothena Co. plc (NASDAQ:PRTA)
Corebridge Financial Inc. trimmed its position in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 7.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,140 shares of the biotechnology company’s stock after selling 1,596 shares during the quarter. […] - 2025-04-11 05:40:59
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Rating of “Moderate Buy” by Analysts
Prothena Co. plc (NASDAQ:PRTA – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among […] - 2025-04-11 04:32:50
KLP Kapitalforvaltning AS Acquires New Shares in Prothena Co. plc (NASDAQ:PRTA)
KLP Kapitalforvaltning AS acquired a new position in Prothena Co. plc (NASDAQ:PRTA – Free Report) in the fourth quarter, HoldingsChannel reports. The fund acquired 12,900 shares of the biotechnology company’s stock, valued at approximately $179,000. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PRTA. Orion Portfolio […] - 2025-04-09 04:28:47

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc PRTA holdings

DateNumber of PRTA Shares HeldBase Market Value of PRTA SharesLocal Market Value of PRTA SharesChange in PRTA Shares HeldChange in PRTA Base ValueCurrent Price per PRTA Share HeldPrevious Price per PRTA Share Held
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PRTA by Blackrock for IE00B3VWM098

Show aggregate share trades of PRTA

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-08-21SELL-2208.5608.570 8.569USD -1,885 10.92 Profit of 518 on sale
2025-08-06SELL-4547.9208.010 8.001USD -3,632 11.05 Profit of 1,385 on sale
2025-08-04SELL-4546.9406.990 6.985USD -3,171 11.10 Profit of 1,866 on sale
2025-07-31BUY6816.8707.225 7.189USD 4,896 11.14
2025-07-28SELL-2276.8706.890 6.888USD -1,564 11.21 Profit of 982 on sale
2025-07-25SELL-2276.6806.860 6.842USD -1,553 11.24 Profit of 999 on sale
2025-06-30SELL-4566.0706.240 6.223USD -2,838 11.82 Profit of 2,554 on sale
2025-06-25SELL-2285.9906.140 6.125USD -1,396 11.94 Profit of 1,325 on sale
2025-06-20SELL-4565.7206.050 6.017USD -2,744 12.06 Profit of 2,754 on sale
2025-05-23BUY2286.5806.615 6.611USD 1,507 13.09
2025-05-19SELL-2287.4007.410 7.409USD -1,689 13.29 Profit of 1,340 on sale
2025-05-15SELL-6846.7156.920 6.900USD -4,719 13.39 Profit of 4,437 on sale
2025-05-12SELL-2287.6108.050 8.006USD -1,825 13.54 Profit of 1,261 on sale
2025-05-09SELL-2287.4308.080 8.015USD -1,827 13.59 Profit of 1,270 on sale
2025-04-30SELL-2289.2009.575 9.537USD -2,175 13.93 Profit of 1,001 on sale
2025-04-24SELL-4569.6509.980 9.947USD -4,536 14.08 Profit of 1,885 on sale
2025-04-17SELL-2289.2009.485 9.456USD -2,156 14.31 Profit of 1,106 on sale
2025-04-15SELL-6849.59010.042 9.997USD -6,838 14.40 Profit of 3,012 on sale
2025-04-14SELL-6849.94010.450 10.399USD -7,113 14.44 Profit of 2,767 on sale
2025-04-09SELL-91210.26010.790 10.737USD -9,792 14.58 Profit of 3,502 on sale
2025-04-07SELL-1,59610.84011.280 11.236USD -17,933 14.66 Profit of 5,461 on sale
2025-04-04SELL-2,28010.86011.370 11.319USD -25,807 14.70 Profit of 7,703 on sale
2025-03-31BUY22812.37512.705 12.672USD 2,889 14.78
2025-03-19SELL-45612.88013.280 13.240USD -6,037 14.95 Profit of 778 on sale
2025-03-14SELL-1,36813.74014.340 14.280USD -19,535 15.00 Profit of 988 on sale
2025-03-13SELL-45814.07014.285 14.263USD -6,533 15.01 Profit of 343 on sale
2025-03-12SELL-7,78613.86014.240 14.202USD -110,577 15.03 Profit of 6,430 on sale
2025-03-07SELL-45815.27015.626 15.590USD -7,140 15.05 Loss of -249 on sale
2025-03-06SELL-68715.13015.540 15.499USD -10,648 15.05 Loss of -311 on sale
2025-03-03SELL-22914.33016.048 15.876USD -3,636 15.06 Loss of -188 on sale
2025-02-28SELL-1,37415.81016.160 16.125USD -22,156 15.05 Loss of -1,482 on sale
2025-02-26SELL-22914.55015.080 15.027USD -3,441 15.05 Profit of 6 on sale
2025-02-25SELL-68714.63015.390 15.314USD -10,521 15.06 Loss of -176 on sale
2025-02-18BUY1,14513.91014.725 14.644USD 16,767 15.06
2025-02-13BUY22913.89013.920 13.917USD 3,187 15.11
2025-02-12BUY22913.82013.920 13.910USD 3,185 15.13
2025-02-11BUY68713.79014.110 14.078USD 9,672 15.16
2025-02-06BUY2,06114.44014.950 14.899USD 30,707 15.21
2025-01-27BUY22916.04016.640 16.580USD 3,797 15.25
2025-01-22SELL-45814.43014.770 14.736USD -6,749 15.26 Profit of 240 on sale
2025-01-17SELL-22913.77014.400 14.337USD -3,283 15.36 Profit of 234 on sale
2025-01-16BUY22913.18013.490 13.459USD 3,082 15.41
2025-01-14BUY68712.67013.410 13.336USD 9,162 15.54
2025-01-13BUY45813.13013.300 13.283USD 6,084 15.60
2025-01-08BUY1,37414.16014.250 14.241USD 19,567 15.76
2024-12-30BUY1,14514.88015.250 15.213USD 17,419 15.85
2024-12-06BUY91614.05014.560 14.509USD 13,290 16.00
2024-12-05BUY22913.93014.675 14.601USD 3,344 16.07
2024-12-04BUY1,14514.53014.700 14.683USD 16,812 16.12
2024-11-29BUY1,14016.21016.365 16.349USD 18,638 16.26
2024-11-27BUY91215.88016.040 16.024USD 14,614 16.29
2024-11-26BUY22815.58015.890 15.859USD 3,616 16.32
2024-11-21BUY1,14014.44014.700 14.674USD 16,728 16.58
2024-11-20BUY68414.40014.580 14.562USD 9,960 16.70
2024-11-18BUY2,73613.51014.155 14.090USD 38,552 17.07
2024-11-12BUY1,82417.36018.000 17.936USD 32,715 17.05
2024-11-08BUY1,14017.70017.920 17.898USD 20,404 17.00
2024-11-07BUY3,40517.49018.645 18.530USD 63,093 16.96
2024-11-06BUY45418.35018.775 18.732USD 8,505 16.85
2024-10-31BUY22717.00018.140 18.026USD 4,092 16.90
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PRTA

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19108,3170182,19359.5%
2025-09-1865,5460159,08441.2%
2025-09-1788,134851183,39448.1%
2025-09-1656,7370121,37146.7%
2025-09-15120,935188321,91237.6%
2025-09-1279,6070177,44344.9%
2025-09-1195,3740287,70133.2%
2025-09-1056,2860176,09032.0%
2025-09-09102,797200405,12325.4%
2025-09-0880,7590241,85433.4%
2025-09-0579,4740527,64115.1%
2025-09-04129,8930344,75837.7%
2025-09-03101,0660507,34919.9%
2025-09-0279,7730480,12516.6%
2025-08-29137,2870380,23736.1%
2025-08-28251,36427,779681,66236.9%
2025-08-2782,656202371,97522.2%
2025-08-2663,2193,211241,51626.2%
2025-08-2587,2910233,97237.3%
2025-08-2276,1540487,31115.6%
2025-08-2182,6000393,33521.0%
2025-08-2056,4090225,10425.1%
2025-08-1989,0140357,09324.9%
2025-08-18107,5970529,22520.3%
2025-08-1570,4150445,98115.8%
2025-08-1452,5920203,47725.8%
2025-08-1392,6680629,88714.7%
2025-08-12111,52713,821344,14432.4%
2025-08-11110,1990376,93329.2%
2025-08-08155,2750374,24441.5%
2025-08-07120,9430251,06948.2%
2025-08-06339,64917,3561,549,64221.9%
2025-08-05251,73419,116638,38839.4%
2025-08-04113,26564364,14431.1%
2025-08-01130,04479324,25340.1%
2025-07-31132,258534337,23139.2%
2025-07-30179,5896,037653,05927.5%
2025-07-29148,926111328,23245.4%
2025-07-28110,0970308,96535.6%
2025-07-25105,6560379,13427.9%
2025-07-2483,1560295,01028.2%
2025-07-23106,1090341,01231.1%
2025-07-2273,0320249,70129.2%
2025-07-21119,0400249,41847.7%
2025-07-18124,7040299,01841.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy